KEGG   DRUG: OlaratumabHelp
Entry
D09939                      Drug                                   

Name
Olaratumab (USAN/INN);
Olaratumab (genetical recombination) (JAN);
Lartruvo (TN)
Product
Formula
C6554H10076N1736O2048S40
Exact mass
147148.6495
Mol weight
147239.1336
Sequence
(Heavy chain)
QLQLQESGPG LVKPSETLSL TCTVSGGSIN SSSYYWGWLR QSPGKGLEWI GSFFYTGSTY
YNPSLRSRLT ISVDTSKNQF SLMLSSVTAA DTAVYYCARQ STYYYGSGNY YGWFDRWDQG
TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP
APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Light chain)
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPAFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H97, H154-H210, H271-H331, H377-H435, H236-H'236, H239-H'239, L23-L88, L134-L194, H230-L214)
  Type
Peptide
Remark
ATC code: L01XC27
Product: D09939<US>
Efficacy
Antineoplastic, Anti-platelet-derived growth factor (PDGF) receptor alpha antibody
Comment
Monoclonal antibody
Target
PDGFRA [HSA:5156] [KO:K04363]
  Pathway
hsa04010  MAPK signaling pathway
hsa05200  Pathways in cancer
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC27 Olaratumab
      D09939  Olaratumab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Olaratumab
    D09939  Olaratumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   PDGFR family
    PDGFRA
     D09939  Olaratumab (USAN/INN) <US>
Antineoplastics [br08340.html]
 D09939
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09939
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09939
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09939
BRITE hierarchy
Other DBs
CAS: 1024603-93-7
PubChem: 124490624
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system